ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2224

Oral Contraceptive Pill Use in Women with Ankylosing Spondylitis Is Associated with a Younger Age At Diagnosis

Dharini Mahendira1, Arane Thavaneswaran2, Adele Carty3, Nigil Haroon4, Ammepa Anton5, Laura A. Passalent6, Khalid A. Alnaqbi3, Laurie M. Savage7, Elin Aslanyan7 and Robert D. Inman8, 1Rheumatology, St Michael's Hospital, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 4Medicine/Rheumatology, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada, 5Rheumatology, University Health Network, Toronto, ON, Canada, 6Allied Health, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 7Spondylitis Association of America, Van Nuys, CA, 8Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), diagnosis and women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: While AS is traditionally recognized as a predominantly male disease, the impact of gender differences on AS pathogenesis has not been clearly established. Specifically, the potential role of sex hormones in mediating gender impact on both AS susceptibility and disease severity remains unanswered. Both exogenous and endogenous estrogens may play a key role in AS disease expression in women. Our objective is to elucidate the potential impact of exogenous estrogen on AS initiation and severity. We hypothesized that exogenous estrogen, in the form of oral contraceptive pills (OCP), may alter AS disease activity and severity in premenopausal women.

Methods: The study population consists of premenopausal women with AS seen in our longitudinal clinic, as well as members of the Spondylitis Association of America (SAA). Measures of disease severity included: use of biological agents, hip replacement surgery, and BASFI scores as a surrogate marker of disability. A patient questionnaire was created and used to obtain information on patient demographics, past and present OCP use, menstrual history, pregnancy history, AS duration, medication use, and hip replacement.

Results: A total of 655 women participated in this study. This was comprised of 516 OCP users and 139 non-OCP users. The mean age of OCP users was 42.2 (+/- 11.5) and 47.9 (+/- 12.2) years in non-OCP users.  While no difference was noted with respect to initial onset of back pain, OCP users were significantly younger at the age of diagnosis of AS (35.7 years vs. 38.6 years, p=0.01). (Table) There was no significant difference in anti-TNF or opioid use, pregnancy complications, nor rates of hip surgery between OCP and non-OCP users. A trend towards higher rate of pregnancy complications was noted in all OCP users, although this was not statistically significant (45.4% vs. 36.5%, p=0.13). There was no significant difference in reported BASFI scores between the groups.

Conclusion: The use of exogenous estrogens in the form of oral contraceptive pills is associated with a significantly earlier diagnosis of AS in women. To date, this is the largest study investigating the potential impact of exogenous estrogens in women with AS. While exogenous estrogens are not associated with surrogate indicators of disease severity, the earlier age of diagnosis of AS amongst women taking OCP suggests hormone modulation of disease expression in the early stages of disease.

Table: Women with AS – Clinical Features in OCP Users vs Non-users

 

 OCP Users

(n=516)

Non-OCP Users

 (n=139)

 

P-value

Age at diagnosis of AS

35.7 (11.2)

38.6 (12.2)

0.01

Age at onset of back pain

24.1 (10.2)

24.7 (10.5)

0.52

Race (% Caucasian)

457 (90.7%)

112 (83.0%)

0.02

Use of Anti-TNF agents

330 (64%)

80 (58.4%)

0.23

Use of Opioids

186 (41.5%)

56 (45.5%)

0.47

Past hip surgery

20 (4.4%)

8 (6.5%)

0.34

Past pregnancy complications

152 (45.4%)

35 (36.5%)

0.13


Disclosure:

D. Mahendira,
None;

A. Thavaneswaran,
None;

A. Carty,
None;

N. Haroon,
None;

A. Anton,
None;

L. A. Passalent,
None;

K. A. Alnaqbi,
None;

L. M. Savage,
None;

E. Aslanyan,
None;

R. D. Inman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oral-contraceptive-pill-use-in-women-with-ankylosing-spondylitis-is-associated-with-a-younger-age-at-diagnosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology